Tesamorelin

A well-characterized GHRH analog offering researchers a focused way to examine pituitary signaling, endogenous growth-hormone release, IGF-1 response, and body-composition pathways.

Primary research pathwaysGHRH · GH/IGF-1 axis

In simple termsGrowth-hormone signaling and research involving visceral—or deep abdominal—fat in a specific clinical population.

Scientific overview

What is Tesamorelin?

Tesamorelin is a synthetic GHRH analog that stimulates endogenous pulsatile growth-hormone release and downstream IGF-1 signaling. It has an FDA-approved prescription use for reducing excess abdominal fat in adults with HIV and lipodystrophy; that approval does not extend to general weight loss.

Mechanism under study

How researchers examine it

Tesamorelin binds pituitary GHRH receptors, increasing GH secretion and IGF-1. In its approved population, trials measured changes in visceral adipose tissue rather than treating obesity or producing general weight loss.

Evidence landscape

What the research currently shows

FDA-reviewed trials found reductions in visceral adipose tissue in the approved population, with effects maintained during continued treatment and reaccumulation after discontinuation. Those findings apply to a specific prescription product and studied population.

Research focus

Why it stands out

A well-characterized GHRH analog that stimulates endogenous growth-hormone signaling.
Allows focused study of the GH and IGF-1 axis and related body-composition pathways.
Supported by a comparatively developed clinical research history in a defined population.